Virion Therapeutics to Speak at ACCESS CHINA BD Forum @ BIO

June 15, 2025 (Boston) — We are glad to announce that Dr. Sue Currie, the Chief Operating Officer of Virion Therapeutics, will be presenting at the ACCESS CHINA BD Forum @BIO on June 15, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.

About Virion Therapeutics

Virion is a clinical stage company developing novel T cell-based immunotherapies for cancer and infectious diseases. What makes Virion unique is their proprietary technology, known as checkpoint modifiers, which alters T cell activation to enhance and broaden responses to include regions of cancers and infectious diseases that are not normally stimulated during a chronic disease. This disruptive, first in class immune modulator, “removes the brakes AND hits the gas” on the immune system.

Virion’s Lead Clinical Program, VRON-0200, which has sites in the APAC region (Hong Kong and New Zealand), recently presented data at a Global European Liver Meeting, EASL, and a Global Asian Liver Meeting in Beijing, that many experts have commented have a high potential to change the HBV functional cure landscape with VRON-0200 as the backbone treatment for functional cure.

About the speaker

Dr. Sue Currie serves as Chief Operating Officer of Virion Therapeutics, LLC, where she and the Company continue to pursue a safe, convenient, accessible, and effective treatment for functional cure for chronic hepatitis B for the 300+ million persons affected by this disease. Virion’s platform technologies, and pipeline, that includes IND-enabling activities for their lead cancer program, offer a novel checkpoint modifier containing mechanism to help restore a patient’s own immune response against cancer and chronic infection.

Sue has 20+ years of strategic, clinical, and scientific leadership, not only within biotechnology and different pharma companies, but also in Veterans Health Administration, academic, correctional health, and community care settings. Additionally, Sue has authored numerous pivotal scientific publications in immuno-oncology and infectious diseases and is a Biotech Leader in the field.

About ACCESS CHINA BD Forum @BIO

‘ACCESS CHINA BD Forum @BIO is scheduled to be held on June 15, 2025, at Seaport Boston Hotel. This year’s ACCESS CHINA BD Forum @BIO will convene 80 distinguished guests for an afternoon of strategic networking, business development, and thought leadership, with a special emphasis on China’s dynamic biotechnology landscape and global collaboration opportunities.

Conference Name: ACCESS CHINA BD Forum @BIO

Date: June 15, 2025

Content: Keynote Speeches, Panel Discussion, 10 Elevator Pitch, and Closed-Door Dinner Reception.

Participants: Pharma/Biotech senior management and BD’s

View more information at https://biotochina.org/